Cancer Management and Research · 2012 · 16 citations · 35 references
MedicineOncologyPharmacologyMetastasisMolecular OncologyTumor ProgressionCancer Cell SignalingCancer ProgressionMtor Inhibitor TherapyNeuroendocrine Tumor TherapyOncogenic Signaling PathwaysPancreatic CancerEverolimus TreatmentMtor InhibitionPancreatic Neuroendocrine NeoplasmsPhosphatidylinositol 3-Kinase PathwayPhosphatidylinositol 3-Kinase-akt PathwayPhosphatidylinositol 3-Kinase-akt SignalingTumor Cell ProliferationWell-differentiated Neuroendocrine Tumors
Pancreatic neuroendocrine tumors are rare and the majority of patients present in the advanced stage. Over the past few decades, treatment for patients with metastatic well- or moderately differentiated pancreatic neuroendocrine tumors have not significantly impeded tumor progression nor improved survival. However, recent mapping of intracellular signaling pathways promoting tumor proliferation, growth, and angiogenesis has presented mammalian target of rapamycin (mTOR) as a potential target within the phosphatidylinositol 3-kinase-Akt pathway. With the development of the new-generation mTOR inhibitor everolimus, a series of clinical trials over the last 5 years have demonstrated significant benefit in delaying tumor progression. This review focuses on the mechanism of mTOR inhibition and traces the development of clinical evidence for the use of mTOR inhibitors in well- to moderately differentiated advanced pancreatic neuroendocrine tumors.
35
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research · 2006 · 2.6K citations · Full text
Medicine, Oncology, Pharmacology +16
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine · 2011 · 2.5K citations
Medicine, Oncology, Pharmacology +11
Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations
Medicine, Oncology, Pharmacotherapy +17